Discordance Between Cerebral Spinal Fluid and Plasma HIV Replication in Patients with Neurological Symptoms Who Are Receiving Suppressive Antiretroviral Therapy
about
Cerebrospinal fluid analysis in the HIV infection and compartmentalization of HIV in the central nervous systemChronic inflammation and the role for cofactors (hepatitis C, drug abuse, antiretroviral drug toxicity, aging) in HAND persistenceRecent developments in human immunodeficiency virus-1 latency researchThe Chronicity of HIV Infection Should Drive the Research Strategy of NeuroHIV Treatment Studies: A Critical ReviewTargeting the Brain Reservoirs: Toward an HIV CureNeurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapyEffectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysisHIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment.Alarmins and central nervous system inflammation in HIV-associated neurological disorders.Relationship of Human Immunodeficiency Virus Viral Load in Cerebrospinal Fluid and Plasma in Patients Co-infected With Cryptococcal Meningitis.Diffuse White Matter Signal Abnormalities on Magnetic Resonance Imaging Are Associated With Human Immunodeficiency Virus Type 1 Viral Escape in the Central Nervous System Among Patients With Neurological SymptomsTemporal Patterns and Drug Resistance in CSF Viral Escape Among ART-Experienced HIV-1 Infected AdultsPathogenesis of HIV in the central nervous systemThe cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIV.HIV-associated neurocognitive disorder.Evolving character of chronic central nervous system HIV infection.Cerebrospinal fluid can be used for HIV genotyping when it fails in blood.The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence?Asymptomatic neurocognitive disorders in patients infected by HIV: fact or fiction?ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects.Classification models for neurocognitive impairment in HIV infection based on demographic and clinical variables.HIV, dementia and antiretroviral drugs: 30 years of an epidemic.HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatmentHIV-associated neurocognitive disorders: perspective on management strategiesImpact of antiretroviral therapy on HIV-related brain injury.Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection.Controversies in HIV-associated neurocognitive disordersNeuropathogenesis of HIV-associated neurocognitive disorders: roles for immune activation, HIV blipping and viral tropismEffect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations.Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapyHepatitis B virus compartmentalization in the cerebrospinal fluid of HIV-infected patientsMorphine potentiates neurodegenerative effects of HIV-1 Tat through actions at μ-opioid receptor-expressing glia.The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer's disease.The cerebrospinal fluid proteome in HIV infection: change associated with disease severityHIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment.Leveraging Cancer Therapeutics for the HIV Cure Agenda: Current Status and Future DirectionsInduction of Heme Oxygenase-1 Deficiency and Associated Glutamate-Mediated Neurotoxicity Is a Highly Conserved HIV Phenotype of Chronic Macrophage Infection That Is Resistant to Antiretroviral TherapyVirological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders.Validation of the International HIV Dementia Scale as a Screening Tool for HIV-Associated Neurocognitive Disorders in a German-Speaking HIV Outpatient Clinic.Central nervous system viral invasion and inflammation during acute HIV infection.
P2860
Q26801033-3E606C09-B79C-49C5-83FC-D60EA81D7775Q26825762-D4224595-68FB-4E09-BFE3-1EA7E8ED5771Q27013114-FCDAC48D-C1C1-411C-9B8D-CFBA3A60FCE2Q28066725-A0A7DD7D-A137-4B58-8761-9A791677C9C2Q28075694-40D530C1-EE16-4FCB-A709-A95AD7D8373BQ28534903-35CDD73E-9E24-4571-BF95-342D12C45988Q28742423-ADFBF21E-3C2A-4E99-B20E-457450D6147FQ30234305-ACAA640A-3DBF-4D8E-B13B-831BCA633CD6Q30241037-EB4D9467-518F-449E-866D-22CD495678F8Q33609454-EEFD7E4C-BE81-411C-9374-CEC3E3B114F7Q33712027-0F563302-2F06-49BD-AE6D-CA9F205A5803Q33750994-BE2C1816-131E-4AF5-8343-042DB171C16EQ33781978-3B606A6E-652F-468B-ABA6-992AA0807C59Q33938797-CC437C46-85C2-49C2-9AFB-36D821DE2B36Q33939729-94496BEF-7ECA-4B45-A029-37487712A631Q33995713-6C18A55C-0CDA-4EF2-8ECA-9BED2413B120Q34070231-9AAA191F-6949-4F9A-A38B-40C4575F6021Q34113072-14497E06-AB2D-44A8-A3D8-F487D660A61AQ34113118-F057D4F7-9EC6-4E67-996B-011A5ECD5CA0Q34202181-5E2BBFD7-949E-43A1-B906-56188813F0E8Q34215731-2B9AE901-D9F2-49EF-888A-413B72137503Q34573511-DC60CCC9-15D1-444A-A51E-17F241362193Q34644242-E63E6404-D786-43D0-9211-800D22DBF821Q34652590-1FBC3BDB-8549-4FD4-9039-C45B44B0CDCCQ34699119-7261E915-951E-4F62-838C-6CD284FD3460Q34776835-2F7E3F8F-8B2F-4118-84C4-0D7B62841A94Q35037015-05F0049F-D485-4540-BB34-E865CB12F5FBQ35057044-6D2553B3-AA0C-4A3E-9F06-2E8F325DE704Q35404442-9422B151-D020-4DDE-814E-3CC047C88950Q35532868-F3C4AD03-A7F1-498A-8C08-92136F2BF706Q35582552-239B6714-E7B2-4233-92EE-134A18829D4DQ35606725-F85D178C-25D0-4555-A16B-D4B1E6B45EC3Q35848870-96C2D75F-761B-4FCB-A566-A0B4BCF5F176Q35965332-BE52E86A-2D33-41E0-B622-8812D3474986Q36009246-B4056511-96CA-4AEA-A198-CE784360ED2BQ36030989-9687A370-17D6-4233-A143-1401B3CE046FQ36086223-6AA2915E-C735-45F5-90EF-13CC695E7CA6Q36204440-A4BE4DEF-CBEC-42A2-AE6B-F310BFCD874CQ36228243-42856B0F-4081-47B8-89E8-70AC76CCD50AQ36376213-59EA8DD6-64E8-4641-BB5F-9F8DA58E9C57
P2860
Discordance Between Cerebral Spinal Fluid and Plasma HIV Replication in Patients with Neurological Symptoms Who Are Receiving Suppressive Antiretroviral Therapy
description
article
@en
im März 2010 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в березні 2010
@uk
name
Discordance Between Cerebral S ...... ressive Antiretroviral Therapy
@en
Discordance Between Cerebral S ...... ressive Antiretroviral Therapy
@nl
type
label
Discordance Between Cerebral S ...... ressive Antiretroviral Therapy
@en
Discordance Between Cerebral S ...... ressive Antiretroviral Therapy
@nl
prefLabel
Discordance Between Cerebral S ...... ressive Antiretroviral Therapy
@en
Discordance Between Cerebral S ...... ressive Antiretroviral Therapy
@nl
P2093
P50
P356
P1476
Discordance Between Cerebral S ...... ressive Antiretroviral Therapy
@en
P2093
Ana Canestri
Anne Geneviève Marcelin
Corinne Amiel
François‐Xavier Lescure
Gilles Pialoux
Roland Tubiana
P304
P356
10.1086/650538
P407
P577
2010-03-01T00:00:00Z